信息来源：http://www.fluidigm.com/pr/news020209.html

Fluidigm公司2009年2月2日宣称，英国剑桥大学Cancer Research UK Centre for Genetic Epidemiolog研究中心已经购买了Fluidigm公司的EP1系统用于癌症和疾病的研究。Fluidigm的1系统是一套小型、高效、高通量、价格实惠的基于集成流体管道（IFC）技术的基因分析系统。

Monday, February 2, 2009; South San Francisco, CA; Cambridge, UK – Fluidigm Corporation today announced that the Cancer Research UK Centre for Genetic Epidemiology, University of Cambridge, based at Strangeways Research Laboratory in the United Kingdom, has purchased the company’s EP1 System to conduct cancer research and disease association studies. The Fluidigm EP1 system combines the efficiencies of integrated fluidic circuit (IFC)-based high-throughput genotyping in a desktop-sized configuration, with a very affordable system price.

The Centre for Genetic Epidemiology is using high-throughput SNP genotyping to identify and verify genetic variants that can underlie susceptibility to various cancers. Cancers that are being investigated include breast, ovarian, colorectal, prostate, and melanoma. The lab uses an automated process with sample tracking and quality control.  The Centre has successfully completed its validation experiments on the EP1 system using real samples and will now move forward using the system in its large genotyping studies.

“With a high-throughput genotyping lab already in place here at Strangeways, Fluidigm’s integrated fluidic circuits offered us an exciting new technology where we could use reliable TaqMan® chemistry with the added ability of assaying 96 SNPs at a time,” said Craig Luccarini, Senior Technical Officer, Strangeways Research Laboratory.  “Piloting of the EP1 system generated data of good quality and the system fitted well in our lab as a robust process, capable of genotyping thousands of DNA samples, all at a competitive cost per genotype.”

“The Centre for Genetic Epidemiology is undertaking important research focusing on understanding the determinants of common disease and how to prevent them. Their work can make a noteworthy difference in people’s lives,” said Gajus Worthington, Fluidigm president and chief executive officer. “We believe the attributes of our EP1 system can help them speed toward the answers they seek.”

Strangeways Research Laboratory is known for its exploration surrounding identification and prevention of common diseases with a genetic component. They use a wide range of disciplines relevant to a given field, and bring together researchers in epidemiology, molecular genetics, bioinformatics, statistics and public health. This interdisciplinary approach is a particular strength of Strangeways Research Laboratory.

Fluidigm’s EP1 system, combined with the company’s IFCs called dynamic arrays, provide superior data quality, a fast and easy workflow, and significant cost savings for high-throughput SNP genotyping studies. The EP1 system delivers the highest quality SNP genotyping results on the market with better than 99 percent call rates and 99.75 percent or greater accuracy. All of this is achieved with an easy-to-use, high-throughput workflow that can provide up to 9,216 data points per IFC with results in just four hours. 

The EP1 system, which includes the IFC Controller, Stand-Alone Thermal Cycler and End Point Reader, provides over 27,000 genotypes a day. By adding more IFC controllers and thermal cyclers to be used in conjunction with a single EP1 Reader, laboratories can generate more than 200,000 genotypes in a day using TaqMan chemistries.

About Fluidigm

Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These “integrated circuits for biology” are made possible by miniaturizing and integrating liquid handling components on a single microfabricated device (chip). Fluidigm’s IFC systems, consisting of instrumentation, software and single-use IFCs, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the Food and Drug Administration for use as a diagnostic and are only available for research use.